Partnering with TGV Therapeutics

partneringTGV-Therapeutics is dedicated to the development of inhaled Mul-1867-CF to treat lung infections in CF patients. As a research-based and innovation-driven company, we devote our science to deepen the understanding of pathological processes that has revealed new approaches for life saving drugs development. We believe that we can best achieve these goals together with partners combining our strengths and capabilities.
We are interested in establishing development partners for Mul-1867-CF. If interested, please contact tets@tgvlabs.com.